Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 May;27(5):527–537. doi: 10.1111/j.1365-2125.1989.tb03414.x

Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

D B Barnett 1
PMCID: PMC1379917  PMID: 2547407

Full text

PDF
527

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons R. D., Molinoff P. B. Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. J Pharmacol Exp Ther. 1982 May;221(2):439–443. [PubMed] [Google Scholar]
  2. Anderson J. L., Lutz J. R., Gilbert E. M., Sorensen S. G., Yanowitz F. G., Menlove R. L., Bartholomew M. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1985 Feb 1;55(4):471–475. doi: 10.1016/0002-9149(85)90396-0. [DOI] [PubMed] [Google Scholar]
  3. Apperley G. H., Drew G. M., Sullivan A. T. Prenalterol is an agonist at beta 2- as well as at beta 1-adrenoceptors. Eur J Pharmacol. 1982 Jul 30;81(4):659–663. doi: 10.1016/0014-2999(82)90356-9. [DOI] [PubMed] [Google Scholar]
  4. Ask J. A., Stene-Larsen G., Helle K. B., Resch F. Functional beta 1- and beta 2-adrenoceptors in the human myocardium. Acta Physiol Scand. 1985 Jan;123(1):81–88. doi: 10.1111/j.1748-1716.1985.tb07564.x. [DOI] [PubMed] [Google Scholar]
  5. Bhatia S. J., Swedberg K., Chatterjee K. Acute hemodynamic and metabolic effects of ICI 118,587 (Corwin), a selective partial beta 1 agonist, in patients with dilated cardiomyopathy. Am Heart J. 1986 Apr;111(4):692–696. doi: 10.1016/0002-8703(86)90101-8. [DOI] [PubMed] [Google Scholar]
  6. Bobik A., Little P. J. Role of cyclic AMP in cardiac beta-adrenoceptor desensitization: studies using prenalterol and inhibitors of phosphodiesterase. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):795–801. doi: 10.1097/00005344-198409000-00009. [DOI] [PubMed] [Google Scholar]
  7. Bonow R. O., Bacharach S. L., Green M. V., Kent K. M., Rosing D. R., Lipson L. C., Leon M. B., Epstein S. E. Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation. 1981 Aug;64(2):315–323. doi: 10.1161/01.cir.64.2.315. [DOI] [PubMed] [Google Scholar]
  8. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  9. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  10. Brodde O. E., Schüler S., Kretsch R., Brinkmann M., Borst H. G., Hetzer R., Reidemeister J. C., Warnecke H., Zerkowski H. R. Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1235–1242. doi: 10.1097/00005344-198611000-00021. [DOI] [PubMed] [Google Scholar]
  11. Brückner R., Meyer W., Mügge A., Schmitz W., Scholz H. Alpha-adrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol. 1984 Apr 6;99(4):345–347. doi: 10.1016/0014-2999(84)90144-4. [DOI] [PubMed] [Google Scholar]
  12. Cohn J. N., Franciosa J. A. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med. 1977 Aug 4;297(5):254–258. doi: 10.1056/NEJM197708042970506. [DOI] [PubMed] [Google Scholar]
  13. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  14. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  15. Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. N Engl J Med. 1986 Jan 30;314(5):290–299. doi: 10.1056/NEJM198601303140506. [DOI] [PubMed] [Google Scholar]
  16. Cook N., Richardson A., Barnett D. B. Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding. Eur J Pharmacol. 1984 Mar 2;98(3-4):407–412. doi: 10.1016/0014-2999(84)90289-9. [DOI] [PubMed] [Google Scholar]
  17. Dei Cas L., Bolognesi R., Cucchini F., Fappani A., Riva S., Visioli O. Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy. J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):249–253. doi: 10.1097/00005344-198303000-00014. [DOI] [PubMed] [Google Scholar]
  18. Fennell W. H., Taylor A. A., Young J. B., Brandon T. A., Ginos J. Z., Goldberg L. I., Mitchell J. R. Propylbutyldopamine: hemodynamic effects in conscious dogs, normal human volunteers and patients with heart failure. Circulation. 1983 Apr;67(4):829–836. doi: 10.1161/01.cir.67.4.829. [DOI] [PubMed] [Google Scholar]
  19. Firth B. G., Ratner A. V., Grassman E. D., Winniford M. D., Nicod P., Hillis L. D. Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol. Am J Cardiol. 1984 Dec 1;54(10):1331–1336. doi: 10.1016/s0002-9149(84)80092-2. [DOI] [PubMed] [Google Scholar]
  20. Fowler M. B., Laser J. A., Hopkins G. L., Minobe W., Bristow M. R. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 Dec;74(6):1290–1302. doi: 10.1161/01.cir.74.6.1290. [DOI] [PubMed] [Google Scholar]
  21. Gaasch W. H., Levine H. J., Quinones M. A., Alexander J. K. Left ventricular compliance: mechanisms and clinical implications. Am J Cardiol. 1976 Nov 4;38(5):645–653. doi: 10.1016/s0002-9149(76)80015-x. [DOI] [PubMed] [Google Scholar]
  22. Golf S., Hansson V. Effects of beta blocking agents on the density of beta adrenoceptors and adenylate cyclase response in human myocardium: intrinsic sympathomimetic activity favours receptor upregulation. Cardiovasc Res. 1986 Sep;20(9):637–644. doi: 10.1093/cvr/20.9.637. [DOI] [PubMed] [Google Scholar]
  23. Hashimoto T., Shiina A., Toyo-Oka T., Hosoda S., Kondo K. The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest. Br J Clin Pharmacol. 1986 Mar;21(3):259–265. doi: 10.1111/j.1365-2125.1986.tb05188.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hayes J. S., Bowling N., Pollock G. D. Effects of beta adrenoceptor down-regulation on the cardiovascular responses to the stereoisomers of dobutamine. J Pharmacol Exp Ther. 1985 Oct;235(1):58–65. [PubMed] [Google Scholar]
  25. Hedberg A., Mattsson H., Nerme V., Carlsson E. Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat. Naunyn Schmiedebergs Arch Pharmacol. 1984 Mar;325(3):251–258. doi: 10.1007/BF00495952. [DOI] [PubMed] [Google Scholar]
  26. Hedberg A., Minneman K. P., Molinoff P. B. Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart. J Pharmacol Exp Ther. 1980 Mar;212(3):503–508. [PubMed] [Google Scholar]
  27. Hodgson J. M., Aja M., Sorkin R. P. Intermittent ambulatory dobutamine infusions for patients awaiting cardiac transplantation. Am J Cardiol. 1984 Jan 15;53(2):375–376. doi: 10.1016/0002-9149(84)90477-6. [DOI] [PubMed] [Google Scholar]
  28. Kariya T., Wille L. J., Dage R. C. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):509–514. doi: 10.1097/00005344-198205000-00024. [DOI] [PubMed] [Google Scholar]
  29. Katz A. M. Cyclic adenosine monophosphate effects on the myocardium: a man who blows hot and cold with one breath. J Am Coll Cardiol. 1983 Jul;2(1):143–149. doi: 10.1016/s0735-1097(83)80387-8. [DOI] [PubMed] [Google Scholar]
  30. Katz A. M. Role of the contractile proteins and sarcoplasmic reticulum in the response of the heart to catecholamines: an historical review. Adv Cyclic Nucleotide Res. 1979;11:303–343. [PubMed] [Google Scholar]
  31. Kenakin T. P., Ferris R. M. Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):90–97. doi: 10.1097/00005344-198301000-00014. [DOI] [PubMed] [Google Scholar]
  32. LeJemtel T. H., Keung E., Sonnenblick E. H., Ribner H. S., Matsumoto M., Davis R., Schwartz W., Alousi A. A., Davolos D. Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation. 1979 Jun;59(6):1098–1104. doi: 10.1161/01.cir.59.6.1098. [DOI] [PubMed] [Google Scholar]
  33. Ledda F., Marchetti P., Mugelli A. Studies on the positive inotropic effect of phenylephrine: a comparison with isoprenaline. Br J Pharmacol. 1975 May;54(1):83–90. doi: 10.1111/j.1476-5381.1975.tb07413.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Liang C. S., Sherman L. G., Doherty J. U., Wellington K., Lee V. W., Hood W. B., Jr Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation. 1984 Jan;69(1):113–119. doi: 10.1161/01.cir.69.1.113. [DOI] [PubMed] [Google Scholar]
  35. Likoff M. J., Weber K. T., Andrews V., Janicki J. S., Sutton M. S., Wilson H., Rocci M. L., Jr Amrinone in the treatment of chronic cardiac failure. J Am Coll Cardiol. 1984 May;3(5):1282–1290. doi: 10.1016/s0735-1097(84)80189-8. [DOI] [PubMed] [Google Scholar]
  36. Massie B., Bourassa M., DiBianco R., Hess M., Konstam M., Likoff M., Packer M. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation. 1985 May;71(5):963–971. doi: 10.1161/01.cir.71.5.963. [DOI] [PubMed] [Google Scholar]
  37. Mattsson H., Hedberg A., Carlsson E. Intrinsic sympathomimetic activity of the partial agonist prenalterol in relation to beta adrenoceptor interaction in various tissues, in vitro. J Pharmacol Exp Ther. 1983 Mar;224(3):654–661. [PubMed] [Google Scholar]
  38. Møller M., Thayssen P., Alstrup P., Haghfelt T., Andersen P. E., Jr The effect of coronary artery bypass surgery on ventricular arrhythmias. Eur Heart J. 1983 Jan;4(1):26–30. doi: 10.1093/oxfordjournals.eurheartj.a061367. [DOI] [PubMed] [Google Scholar]
  39. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Persson C. G., Erjefält I., Andersson K. E. Positive inotropic and chronotropic effects and coronary vasodilation in vitro by two antiasthmatic xanthines with different abilities to antagonize adenosine. J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):778–785. doi: 10.1097/00005344-198309000-00012. [DOI] [PubMed] [Google Scholar]
  41. Pouleur H., Rousseau M. F., Mengeot P., Veriter C., Vincent M. F., Brasseur L. A. Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new beta 1 adrenoceptor partial agonist, ICI 118,587. Eur Heart J. 1982 Dec;3 (Suppl 500):123–127. [PubMed] [Google Scholar]
  42. Rajfer S. I., Anton A. H., Rossen J. D., Goldberg L. I. Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. N Engl J Med. 1984 May 24;310(21):1357–1362. doi: 10.1056/NEJM198405243102105. [DOI] [PubMed] [Google Scholar]
  43. Reuter H. Properties of two inward membrane currents in the heart. Annu Rev Physiol. 1979;41:413–424. doi: 10.1146/annurev.ph.41.030179.002213. [DOI] [PubMed] [Google Scholar]
  44. Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
  45. Ruffolo R. R., Jr Review important concepts of receptor theory. J Auton Pharmacol. 1982 Dec;2(4):277–295. doi: 10.1111/j.1474-8673.1982.tb00520.x. [DOI] [PubMed] [Google Scholar]
  46. Ruffolo R. R., Jr The pharmacology of dobutamine. Am J Med Sci. 1987 Oct;294(4):244–248. doi: 10.1097/00000441-198710000-00005. [DOI] [PubMed] [Google Scholar]
  47. Sato H., Inoue M., Matsuyama T., Ozaki H., Shimazu T., Takeda H., Ishida Y., Kamada T. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation. 1987 Jan;75(1):213–220. doi: 10.1161/01.cir.75.1.213. [DOI] [PubMed] [Google Scholar]
  48. Sharma B., Goodwin J. F. Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle. Circulation. 1978 Sep;58(3 Pt 1):449–460. doi: 10.1161/01.cir.58.3.449. [DOI] [PubMed] [Google Scholar]
  49. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):134–142. doi: 10.1136/hrt.44.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):117–133. doi: 10.1136/hrt.44.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tada M., Katz A. M. Phosphorylation of the sarcoplasmic reticulum and sarcolemma. Annu Rev Physiol. 1982;44:401–423. doi: 10.1146/annurev.ph.44.030182.002153. [DOI] [PubMed] [Google Scholar]
  52. Thomas J. A., Marks B. H. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978 Feb;41(2):233–243. doi: 10.1016/0002-9149(78)90162-5. [DOI] [PubMed] [Google Scholar]
  53. Tsien R. W. Calcium channels in excitable cell membranes. Annu Rev Physiol. 1983;45:341–358. doi: 10.1146/annurev.ph.45.030183.002013. [DOI] [PubMed] [Google Scholar]
  54. Unverferth D. A., Blanford M., Kates R. E., Leier C. V. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med. 1980 Aug;69(2):262–266. doi: 10.1016/0002-9343(80)90387-3. [DOI] [PubMed] [Google Scholar]
  55. Waagstein F., Reiz S., Ariniego R., Hjalmarson A. Clinical results with prenalterol in patients with heart failure. Am Heart J. 1981 Sep;102(3 Pt 2):548–554. doi: 10.1016/0002-8703(81)90743-2. [DOI] [PubMed] [Google Scholar]
  56. Wetzel B., Hauel N. New cardiotonic agents--a promising approach for treatment of heart failure. Trends Pharmacol Sci. 1988 May;9(5):166–170. doi: 10.1016/0165-6147(88)90031-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES